|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
58,625,000 |
Market
Cap: |
2.00(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$22.72 - $38.73 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
106,505 |
119,208 |
124,343 |
450,780 |
Total Sell Value |
$3,569,126 |
$3,929,526 |
$4,091,741 |
$15,155,681 |
Total People Sold |
2 |
5 |
5 |
6 |
Total Sell Transactions |
7 |
10 |
11 |
37 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
|
2024-03-21 |
4 |
AS |
$35.31 |
$511,677 |
D/D |
(14,491) |
8,570 |
|
- |
|
Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
|
2024-03-21 |
4 |
OE |
$25.30 |
$366,622 |
D/D |
14,491 |
23,061 |
|
- |
|
Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
|
2024-03-20 |
4 |
AS |
$35.31 |
$14,124 |
D/D |
(400) |
8,570 |
|
-1% |
|
Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
|
2024-03-20 |
4 |
OE |
$25.30 |
$10,120 |
D/D |
400 |
8,970 |
|
- |
|
Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
|
2024-03-19 |
4 |
AS |
$35.31 |
$436,573 |
D/D |
(12,364) |
8,570 |
|
-2% |
|
Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
|
2024-03-19 |
4 |
OE |
$25.30 |
$312,809 |
D/D |
12,364 |
20,934 |
|
- |
|
Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
|
2024-03-13 |
4 |
AS |
$33.48 |
$2,104,289 |
D/D |
(62,366) |
8,570 |
|
-0% |
|
Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
|
2024-03-13 |
4 |
OE |
$12.98 |
$1,098,523 |
D/D |
62,366 |
44,686 |
|
- |
|
Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
|
2024-03-12 |
4 |
AS |
$32.99 |
$128,133 |
D/D |
(3,884) |
8,570 |
|
5% |
|
Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
|
2024-03-12 |
4 |
OE |
$12.98 |
$50,414 |
D/D |
3,884 |
12,454 |
|
- |
|
Khattar Jack A. |
President, CEO |
|
2024-02-28 |
4 |
D |
$27.94 |
$469,057 |
D/D |
(16,788) |
915,217 |
|
- |
|
Khattar Jack A. |
President, CEO |
|
2024-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,000 |
932,005 |
|
- |
|
Mottola Frank |
SVP, Quality, GMP, Ops, IT |
|
2024-02-28 |
4 |
D |
$27.94 |
$12,852 |
D/D |
(460) |
7,779 |
|
- |
|
Mottola Frank |
SVP, Quality, GMP, Ops, IT |
|
2024-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
990 |
8,239 |
|
- |
|
Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
|
2024-02-26 |
4 |
AS |
$30.21 |
$151,050 |
D/D |
(5,000) |
8,570 |
|
17% |
|
Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
|
2024-02-26 |
4 |
OE |
$9.13 |
$45,650 |
D/D |
5,000 |
13,570 |
|
- |
|
Martin Tami Tillotson |
Sr. V.P., Regulatory Affairs |
|
2024-02-23 |
4 |
D |
$29.06 |
$14,094 |
D/D |
(485) |
86,933 |
|
- |
|
Martin Tami Tillotson |
Sr. V.P., Regulatory Affairs |
|
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,250 |
87,418 |
|
- |
|
Mottola Frank |
SVP, Quality, GMP, Ops, IT |
|
2024-02-23 |
4 |
D |
$29.06 |
$27,229 |
D/D |
(937) |
7,249 |
|
- |
|
Mottola Frank |
SVP, Quality, GMP, Ops, IT |
|
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
8,186 |
|
- |
|
Dec Timothy C |
Senior Vice-President & CFO |
|
2024-02-23 |
4 |
D |
$29.06 |
$38,185 |
D/D |
(1,314) |
7,190 |
|
- |
|
Dec Timothy C |
Senior Vice-President & CFO |
|
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
8,504 |
|
- |
|
Siebert John M |
Director |
|
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
3,886 |
87,943 |
|
- |
|
Rubin Jonathan |
SVP, Chief Medical Officer |
|
2024-02-23 |
4 |
D |
$29.06 |
$16,477 |
D/D |
(567) |
4,641 |
|
- |
|
Rubin Jonathan |
SVP, Chief Medical Officer |
|
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,250 |
5,208 |
|
- |
|
345 Records found
|
|
Page 1 of 14 |
|
|